Literature DB >> 3490287

Low-dose deoxycoformycin in the treatment of hairy cell leukemia.

E H Kraut, B A Bouroncle, M R Grever.   

Abstract

Ten patients with progressive hairy cell leukemia were treated with 2'deoxycoformycin (dCF) by intravenous bolus (4 mg/m2) given every other week. All ten patients are evaluable for response and nine of the ten patients have achieved a complete remission. In addition to clearing of hairy cells from the bone marrow, eight patients had resolution of their monocytopenia. Seven of the nine patients remain in unmaintained remission with a median duration of 6.2 months. Two patients have had relapse in the bone marrow alone and continue to have normal peripheral blood counts. They are being followed without treatment. Toxicity was minimal at this low dose with one patient having a mild reversible reduction in creatinine clearance. Four other patients had reversible neutropenia. There were no significant infections associated with treatment. Low-dose deoxycoformycin administered intravenously every other week represents an extremely effective treatment for hairy cell leukemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490287

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Hypersensitivity reactions to deoxycoformycin.

Authors:  P J O'Dwyer; S A King; E Eisenhauer; J L Grem; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2'-deoxycoformycin and deoxyadenosine.

Authors:  A Begleiter; L Verburg; L G Israels; J B Johnston
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.

Authors:  A D Ho; K Ganeshaguru
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 4.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

5.  Chemical stability of pentostatin (NSC-218321), a cytotoxic and immunosuppressant agent.

Authors:  L A al-Razzak; A E Benedetti; W N Waugh; V J Stella
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 6.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

7.  A 72-kD B cell-associated surface glycoprotein expressed at high levels in hairy cell leukaemia and plasma cell neoplasms.

Authors:  K Pulford; K Micklem; J Thomas; M Jones; D Y Mason
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

8.  2'-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha.

Authors:  A D Ho; R Kuse; O Prümmer; F Porzsolt; W Hunstein
Journal:  Klin Wochenschr       Date:  1987-10-15

Review 9.  Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.

Authors:  M Schuler; C Huber; C Peschel
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

10.  Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors.

Authors:  Marina Tusup; Thomas M Kündig; Steve Pascolo
Journal:  Mol Ther       Date:  2021-09-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.